Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The investigator(s) hypothesize that Rituximab together with combination chemotherapy, followed by Rituximab maintenance therapy, will provide better disease control with improved response rates and overall survival in patients with previously untreated Mantle Cell Lymphoma (MCL).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Previously untreated, histologically confirmed mantle cell lymphoma,
Measurable or evaluable disease (at least one site with >1.5 cm in diameter
All stages are eligible
Age > 18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
Adequate hepatic function:
Serum creatinine< 1.5 mg/dl
Ability to give informed consent
Women of childbearing potential must have a negative pregnancy test within 72 hours of entering into the study. Males and females must agree to use adequate birth control if conception is possible during the study. Women must avoid pregnancy and men avoid fathering children while in the study.
Life expectancy greater than 6 months.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
25 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal